" class="no-js "lang="en-US"> Cycle Pharmaceuticals Launches Cycle Vita ™, a Dedicated Support Platform for Rare Disease Patients - Medtech Alert
Monday, April 15, 2024

Cycle Pharmaceuticals Launches Cycle Vita ™, a Dedicated Support Platform for Rare Disease Patients

Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of its Boston-based support platform for rare disease patients, Cycle Vita ™.

Cycle Vita ™ provides a vast range of high-quality support programs to both Healthcare Providers and rare disease patients across the United States, who have been prescribed a Cycle treatment.

“Cycle Vita™ is the ultimate expression of the heart of Cycle. At Cycle, we know that a patient’s wellbeing not only depends on life-changing therapy, but the care and support they receive throughout their treatment journey. That is why the Cycle Vita™ support platform provides individualized programs, led by a qualified, dedicated team of experts, to meet the needs of the underserved rare disease community.” said Antonio Benedetti, CEO, Cycle.

Cycle Vita™ will provide appropriate clinical, financial* and emotional support to rare disease patients, as well as product information and support for healthcare professionals with relevant processes to access treatment efficiently.

“Cycle Vita™ has been developed with the idea of individualized patient care at its core. That’s why our nurse product support will be available 24/7, ready to provide appropriate personalized support to patients when they need it. Our team of Access specialists understand how difficult and time consuming it can be to navigate through all the paperwork and processes to access treatment for patients and can help appropriately streamline these processes from enrollment to prescription, and beyond.” said John Reid, Director of Patient Hub services.

Cycle Vita™ begins its journey launching support programs for SAJAZIR™ (icatibant) injection, for patients with Hereditary Angioedema (HAE) providing 24/7 nurse product support, as well as Co-Pay, Bridge, and Quick start financial program support for eligible commercially insured patients.

To find out more about Cycle Vita ™, please visit www.cyclevita.life or call on +1 (888) 360-8482

*Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only.

Cycle Vita ™ and SAJAZIR™ are trademarks of Cycle Pharmaceuticals Limited in the United States.
US-HUB-2100004 – Date of Preparation: September 2021 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more